Floatz logo

Deferasirox

Anemia

NovartisSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Anemia cohort.

Asset / SponsorPhaseRating
Epoetin Alfa
Mayo Clinic
Phase 4BBB
Erythropoietin Human Recombinant
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Epoetin Beta
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BBB
Cyclophosphamide
OHSU Knight Cancer Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

Deferasirox is also rated in:

iron poisoningDormant
A
Indicative ·
82 / 100
View asset →
hemosiderosisDormant
A
Indicative ·
81 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →